Development and validation of an (18)F-FDG PET/CT radiomic nomogram for predicting axillary lymph-node status after neoadjuvant chemotherapy for breast cancer: a multicenter study

构建和验证用于预测乳腺癌新辅助化疗后腋窝淋巴结状态的 (18)F-FDG PET/CT 放射组学列线图:一项多中心研究

阅读:1

Abstract

RATIONALE AND OBJECTIVE: To develop and validate the predictive value of (18)F-FDG PET/CT radiomics models based on data preprocessing methods for axillary lymph-node (ALN) status after neoadjuvant chemotherapy (NAC) for breast cancer. MATERIALS AND METHODS: According to the status of ALN after NAC, we divided the breast cancer patients of the three scanners into the pathological complete remission (pCR) and non-pCR groups, respectively. Totally 630 models were obtained based on various data preprocessing, feature filtering, and modeling approaches. On the one hand, different data preprocessing methods were compared to analyze the advantages of different preprocessing methods. On the other hand, the AUC of predicting ALN status was compared among all models, and the model with the best prediction was obtained. Finally, the optimal model is combined with the clinical and the corresponding Nomogram is plotted. RESULTS: The comparison of the data preprocessing modalities revealed that the model prediction of tumor-to-liver ratio (TLR) radiomics was better than origin radiomics (OR), and the effect of Combat and Limma was better than without batch effects. All preprocessing modalities could be used as a potential method that can further optimize the model. The optimal model had a predicted AUC of 0.798 for ALN status after NAC for breast cancer in the test set and an AUC of 0.811 when combined with clinical characteristics. CONCLUSION: It is necessary to pre-process the data before conducting a study on multicenter data, and the model developed in this way can effectively predict the status of ALN after NAC in breast cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。